ArticleEuropean urology open science2026
Oligoprogressive Renal Cell Carcinoma Treated with Stereotactic Body Radiation Therapy Versus Switching to a New Systemic Therapy.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The promising results of stereotactic body radiation therapy (SBRT) in achieving local control in various primary tumors and metastatic sites have prompted evaluation of its association with outcomes in patients with oligoprogressive metastatic renal cell carcinoma (mRCC) during systemic therapy (ST). This study aimed to describe and compare the clinical outcomes associated with SBRT versus switching ST in patients with oligoprogressive mRCC. Methods: We conducted a single-center retrospective study of patients with mRCC and up to five oligoprogressive extracranial metastases during ST. Patients were categorized into two cohorts: those treated with SBRT without changing ST (group A) and those receiving a change in ST (group B). The primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: A total of 67 patients (group A: 31; group B: 36) treated between 2012 and 2022 were included. After a median follow-up of 46 mo (40 mo for patients alive at the last follow-up), the median PFS was 11 mo in group A and 10 mo in group B ( Conclusion: In this retrospective analysis of patients with oligoprogressive mRCC during ST, SBRT was observed to have similar PFS and OS compared with a strategy of switching to a new ST. These findings are exploratory and do not establish causal effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.